Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-_r8p4pg1kpQnkkGpSAsJNREjUyTW2LZXuivUK-hP2BlzW9Lj-TM5d7NlecksKvsDEFXJWLfPbeF_M5x-jTkcdKGLOWJQ&_hsmi=323800094&utm_content=323781618&utm_source=hs_email